[go: up one dir, main page]

EA200800971A1 - Фармацевтические композиции модулятора 5-нтрецепторов серотонина, полезные в лечении связанных с ними нарушений - Google Patents

Фармацевтические композиции модулятора 5-нтрецепторов серотонина, полезные в лечении связанных с ними нарушений

Info

Publication number
EA200800971A1
EA200800971A1 EA200800971A EA200800971A EA200800971A1 EA 200800971 A1 EA200800971 A1 EA 200800971A1 EA 200800971 A EA200800971 A EA 200800971A EA 200800971 A EA200800971 A EA 200800971A EA 200800971 A1 EA200800971 A1 EA 200800971A1
Authority
EA
Eurasian Patent Office
Prior art keywords
symptoms
anxiety
psychosis
treatment
pharmaceutical compositions
Prior art date
Application number
EA200800971A
Other languages
English (en)
Inventor
Раджеш К. Агарвал
Рампурна Прасад Гуллапалли
Майкл Мартин
Майкл Морган
Деннис Чепмен
Джозеф Белиер Спир
Юнь Шань
Original Assignee
Арена Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арена Фармасьютикалз, Инк. filed Critical Арена Фармасьютикалз, Инк.
Publication of EA200800971A1 publication Critical patent/EA200800971A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к определенным фармацевтическим композициям модулятора 5-HTрецепторов серотонина и способам приготовления соответствующей фармацевтической композиции. Такие фармацевтические композиции полезны в лечении агрегации тромбоцитов, болезни коронарных артерий, инфаркта миокарда, преходящего ишемического нарушения мозгового кровообращения, стенокардии, инсульта, фибрилляции предсердий, в снижении риска образования тромбов, в лечении астмы или ее симптомов, тревожного состояния или симптомов, расстройств поведения, лекарственно индуцированного психоза, эксцитативного психоза, синдрома Тоуретта, маниакального расстройства, органического или NOS-психоза, психического расстройства, психоза, острой шизофрении, хронической шизофрении, NOS-шизофрении и связанных с этим расстройств, нарушений сна, диабет-ассоциированных расстройств, прогрессивной мультифокальной лейкоэнцефалопатии и подобного.
EA200800971A 2005-09-29 2006-09-28 Фармацевтические композиции модулятора 5-нтрецепторов серотонина, полезные в лечении связанных с ними нарушений EA200800971A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72178305P 2005-09-29 2005-09-29
PCT/US2006/038267 WO2007041409A1 (en) 2005-09-29 2006-09-28 Pharmaceutical compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto

Publications (1)

Publication Number Publication Date
EA200800971A1 true EA200800971A1 (ru) 2008-08-29

Family

ID=37686009

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800971A EA200800971A1 (ru) 2005-09-29 2006-09-28 Фармацевтические композиции модулятора 5-нтрецепторов серотонина, полезные в лечении связанных с ними нарушений

Country Status (12)

Country Link
US (1) US20090053306A1 (ru)
EP (1) EP1928430A1 (ru)
JP (1) JP2009510115A (ru)
KR (1) KR20080055963A (ru)
CN (1) CN101272771A (ru)
AU (1) AU2006299656A1 (ru)
BR (1) BRPI0616791A2 (ru)
CA (1) CA2621152A1 (ru)
EA (1) EA200800971A1 (ru)
IL (1) IL190031A0 (ru)
WO (1) WO2007041409A1 (ru)
ZA (1) ZA200802608B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412263B1 (pt) 2003-07-22 2019-10-15 Arena Pharmaceuticals, Inc. Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
WO2005103011A1 (en) * 2004-03-23 2005-11-03 Arena Pharmaceuticals, Inc. Processes for preparing substituted n-aryl-n’-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
EP2161023A3 (en) 2007-04-13 2010-12-29 Southern Research Institute Anti-angiogenic agents and methods of use.
EP2190844B3 (en) 2007-08-15 2013-07-17 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CA2741731A1 (en) * 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
US8974691B2 (en) 2010-09-24 2015-03-10 Fujimi Incorporated Composition for polishing and composition for rinsing
WO2013010169A1 (en) 2011-07-14 2013-01-17 Cook Medical Technologies Llc A sling to be used in the treatment of obstructive sleep apnea
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
EP3072510B1 (en) 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
WO2014189540A1 (en) 2012-10-16 2014-11-27 Catalano Peter J Method and apparatus for treating obstructive sleep apnea (osa)
CA2919504A1 (en) 2013-08-01 2015-02-05 Christine BRONIKOWSKI Tissue adjustment implant
AU2014306232B2 (en) 2013-08-05 2018-12-06 C2Dx, Inc. Medical devices having a releasable tubular member and methods of using the same
US9956384B2 (en) 2014-01-24 2018-05-01 Cook Medical Technologies Llc Articulating balloon catheter and method for using the same
US9974563B2 (en) 2014-05-28 2018-05-22 Cook Medical Technologies Llc Medical devices having a releasable member and methods of using the same
US9913661B2 (en) 2014-08-04 2018-03-13 Cook Medical Technologies Llc Medical devices having a releasable tubular member and methods of using the same
EP4119141A1 (en) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
EP3322415A4 (en) 2015-07-15 2019-03-13 Axovant Sciences GmbH DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE
AU2018294247A1 (en) 2017-06-29 2020-01-23 Cook Biotech Incorporated Implantable medical devices for tissue repositioning
CN114259567A (zh) * 2021-12-29 2022-04-01 中山大学 一种基于bcsⅲ类药物制剂的个性化给药方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412263B1 (pt) * 2003-07-22 2019-10-15 Arena Pharmaceuticals, Inc. Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
AU2006206687A1 (en) * 2005-01-19 2006-07-27 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy

Also Published As

Publication number Publication date
WO2007041409A1 (en) 2007-04-12
AU2006299656A1 (en) 2007-04-12
KR20080055963A (ko) 2008-06-19
ZA200802608B (en) 2009-03-25
IL190031A0 (en) 2008-08-07
JP2009510115A (ja) 2009-03-12
CN101272771A (zh) 2008-09-24
US20090053306A1 (en) 2009-02-26
BRPI0616791A2 (pt) 2011-07-05
EP1928430A1 (en) 2008-06-11
CA2621152A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
EA200800971A1 (ru) Фармацевтические композиции модулятора 5-нтрецепторов серотонина, полезные в лечении связанных с ними нарушений
EA200701101A1 (ru) Производные 3-фенилпиразола в качестве модуляторов 5-htсеротонинового рецептора, полезные для лечения расстройств, связанных с этим рецептором
WO2007120600A3 (en) 3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2007136680A3 (en) 3-pyraz0lyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2007136875A3 (en) Acetamide derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2008054748A3 (en) Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
JO2954B1 (en) Pirazol derivatives used as serotonin 5-Ht2a receptor controllers useful in the treatment of disorders related to these receptors
WO2006060762A3 (en) Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
ECSP066269A (es) Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina útiles para la profilaxis y tratamiento de desórdenes relacionados con el mismo
WO2009023253A3 (en) IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
WO2010062323A3 (en) Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
EA200900623A1 (ru) Бициклические соединения и их применение в качестве противодиабетических средств
BRPI0921369B8 (pt) composto modulador do receptor de prostaciclina (pgi2), sua composição, sua composição farmacêutica, seus usos, bem como processos para a preparação das referidas composições
GT200600083A (es) Derivados de oxiindol
EP2140882A4 (en) MEDICINE FOR THE TREATMENT OF LUNG DISEASES
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
GEP20104961B (en) 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
Guimarães et al. Serotonin in panic and anxiety disorders
MX2008009161A (es) Tratamiento de enfermedad cardiovascular en mexicano-americanos, usando nebivolol.
Ng et al. Stereo-Psychopharmacology: The Case of Citalopram and Escitalopram.
TH86939B (th) อนุพันธ์ไดแอริลและแอริลเฮเทโรแอริลยูเรียเป็นมอดูเลเตอร์ของ 5-ht2a เซอโรโทนินรีเซปเตอร์ที่มีประโยชน์สำหรับการป้องกันและการบำบัดความผิดปกติที่เกี่ยวกับมัน
TH104739A (th) อนุพันธ์ของพิแรโซลเป็นมอดูเลเตอร์ของ 5ht2a เซอโรโทนิน รีเซปเตอร์ ที่มีประโยชน์สำหรับการบำบัดความผิดปกติที่เกี่ยวข้องกับมัน
Mercurio et al. Pulmonary hypertension induced by anticancer drugs
Bundy et al. O-44 Release of heparin binding protein during cardiac surgery: a new mediator of systemic inflammatory response?